Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Jun 28. pii: 96519. doi: 10.1172/JCI96519. [Epub ahead of print]

2.

Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Won Kim T, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2018 Jun 20. doi: 10.1002/cpt.1124. [Epub ahead of print] Review. No abstract available.

PMID:
29923599
3.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

PMID:
29691233
4.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE.

Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330. [Epub ahead of print]

PMID:
29616864
5.

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaam7610. doi: 10.1126/scitranslmed.aam7610.

PMID:
29437148
6.

Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.

Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, Burger DM, van Erp NP.

Ther Drug Monit. 2018 Apr;40(2):222-229. doi: 10.1097/FTD.0000000000000484.

PMID:
29419723
7.

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, Epperly MW, Greenberger JS, Beumer JH, Eiseman JL.

J Pharm Biomed Anal. 2018 Feb 20;150:169-175. doi: 10.1016/j.jpba.2017.12.023. Epub 2017 Dec 12.

PMID:
29245086
8.

Improving Carboplatin Dosing Based on Estimated GFR.

Beumer JH, Inker LA, Levey AS.

Am J Kidney Dis. 2018 Feb;71(2):163-165. doi: 10.1053/j.ajkd.2017.10.005. Epub 2017 Dec 6. No abstract available.

PMID:
29217306
9.

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB.

Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16.

PMID:
29051021
10.

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G, Yen Y.

Breast Cancer Res Treat. 2018 Jan;167(2):469-478. doi: 10.1007/s10549-017-4516-x. Epub 2017 Sep 27.

PMID:
28956187
11.

Estimation of body surface area in the musk shrew ( Suncus murinus): a small animal for testing chemotherapy-induced emesis.

Eiseman JL, Sciullo M, Wang H, Beumer JH, Horn CC.

Lab Anim. 2017 Oct;51(5):534-537. doi: 10.1177/0023677217695851. Epub 2017 Feb 26.

PMID:
28948895
12.

LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.

Kiesel BF, Scemama J, Parise RA, Villaruz L, Iffland A, Doyle A, Ivy P, Chu E, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:244-250. doi: 10.1016/j.jpba.2017.08.037. Epub 2017 Aug 31.

PMID:
28888173
13.

LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.

Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:154-160. doi: 10.1016/j.jpba.2017.08.036. Epub 2017 Aug 31.

PMID:
28881312
14.

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2.

15.

Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, Baburina I, Holleran JL, Beumer JH, Peters GJ, Honeywell RJ, Salamone SJ.

Ther Drug Monit. 2017 Jun;39(3):235-242. doi: 10.1097/FTD.0000000000000402.

16.

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH.

J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7.

PMID:
28387939
17.

Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.

Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP.

Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3986. Epub 2017 May 16.

PMID:
28370076
18.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

PMID:
28356425
19.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

20.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

21.

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D.

Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10.

22.

RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology.

Zhang Y, Hu K, Beumer JH, Bakkenist CJ, D'Argenio DZ.

DNA Repair (Amst). 2017 Apr;52:24-30. doi: 10.1016/j.dnarep.2017.02.004. Epub 2017 Feb 20.

23.

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.

Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:197-205. doi: 10.1016/j.jpba.2017.02.018. Epub 2017 Feb 13.

24.

LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma.

Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:158-165. doi: 10.1016/j.jpba.2017.01.055. Epub 2017 Feb 4.

25.

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.

Vendetti FP, Leibowitz BJ, Barnes J, Schamus S, Kiesel BF, Abberbock S, Conrads T, Clump DA, Cadogan E, O'Connor MJ, Yu J, Beumer JH, Bakkenist CJ.

Sci Rep. 2017 Feb 1;7:41892. doi: 10.1038/srep41892.

26.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G.

Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13.

27.

Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Pore SK, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV.

J Natl Cancer Inst. 2016 Dec 31;109(6). pii: djw293. doi: 10.1093/jnci/djw293. Print 2017 Jun.

28.

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.

Kiesel BF, Parise RA, Wong A, Keyvanjah K, Jacobs S, Beumer JH.

J Pharm Biomed Anal. 2017 Feb 5;134:130-136. doi: 10.1016/j.jpba.2016.11.035. Epub 2016 Nov 22.

29.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP.

Cancer Chemother Pharmacol. 2017 Jan;79(1):201-207. doi: 10.1007/s00280-016-3200-x. Epub 2016 Nov 22.

30.

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):969. No abstract available.

PMID:
27677624
31.

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobbru J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):959-967. Epub 2016 Sep 12. Erratum in: Cancer Chemother Pharmacol. 2016 Nov;78(5):969.

PMID:
27620207
32.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. Epub 2016 Oct 24.

33.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

34.

Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features.

Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E.

Clin Genitourin Cancer. 2017 Feb;15(1):7-22. doi: 10.1016/j.clgc.2016.05.011. Epub 2016 May 31. Review.

PMID:
27473523
35.

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2016 Sep 10;129:359-366. doi: 10.1016/j.jpba.2016.07.027. Epub 2016 Jul 18.

36.

Therapeutic drug monitoring of 5-fluorouracil.

Lee JJ, Beumer JH, Chu E.

Cancer Chemother Pharmacol. 2016 Sep;78(3):447-64. doi: 10.1007/s00280-016-3054-2. Epub 2016 May 23. Review.

37.

Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al.

Beumer JH, Tawbi H, Ivy SP.

J Clin Oncol. 2016 Jul 10;34(20):2430-1. doi: 10.1200/JCO.2016.67.2790. Epub 2016 May 16. No abstract available.

PMID:
27185845
38.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

39.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

40.

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19.

41.

A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Eads JR, Beumer JH, Negrea L, Holleran JL, Strychor S, Meropol NJ.

Cancer Chemother Pharmacol. 2016 Feb;77(2):333-8. doi: 10.1007/s00280-015-2939-9. Epub 2015 Dec 21.

42.

ATM serine-1981 phosphorylation is a plausible biomarker.

Bakkenist CJ, Beumer JH, Schmitz JC.

Cell Cycle. 2015;14(20):3207-8. doi: 10.1080/15384101.2015.1084205. No abstract available.

43.

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.

Beumer JH, Fu KY, Anyang BN, Siegfried JM, Bakkenist CJ.

BMC Cancer. 2015 Oct 5;15:649. doi: 10.1186/s12885-015-1649-3.

44.

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.

Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP.

J Clin Oncol. 2016 Jan 10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. Epub 2015 Sep 21.

45.

Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Deeken JF, Beumer JH, Anders NM, Wanjiku T, Rusnak M, Rudek MA.

Cancer Chemother Pharmacol. 2015 Oct;76(4):813-9. doi: 10.1007/s00280-015-2856-y. Epub 2015 Sep 2.

46.

Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. Epub 2015 Sep 1.

47.

Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.

Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N.

Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19.

48.

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.

Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM.

PLoS One. 2015 Aug 6;10(8):e0134426. doi: 10.1371/journal.pone.0134426. eCollection 2015.

49.

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Parise RA, Eiseman JL, Clausen DM, Kicielinski KP, Hershberger PA, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2015 Sep;76(3):537-46. doi: 10.1007/s00280-015-2828-2. Epub 2015 Jul 21.

50.

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?

Ivy SP, Beumer JH.

JAMA Oncol. 2015 Sep;1(6):732-3. doi: 10.1001/jamaoncol.2015.1926. No abstract available.

Supplemental Content

Loading ...
Support Center